Mumps virus vaccine - Sinovac (Dalian) Vaccine Technology

Drug Profile

Mumps virus vaccine - Sinovac (Dalian) Vaccine Technology

Latest Information Update: 30 Mar 2015

Price : $50

At a glance

  • Originator Sinovac (Dalian) Vaccine Technology
  • Class Viral vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Mumps

Most Recent Events

  • 01 Dec 2012 Launched for Mumps (Prevention) in China (Parenteral)
  • 30 Apr 2010 Sinovac (Dalian) Vaccine Technology files a Clinical Trial Application with the China FDA for its Mumps vaccine candidate
  • 01 Apr 2010 Preclinical trials in Mumps (Prevention) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top